These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 8061423)

  • 1. Contrast-enhanced MR imaging of the liver.
    Runge VM; Pels Rijcken TH; Davidoff A; Wells JW; Stark DD
    J Magn Reson Imaging; 1994; 4(3):281-9. PubMed ID: 8061423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Magnetic resonance imaging of the liver: what kind of contrast agents?].
    De Gaspari A; De Cobelli F; Del Maschio A
    Radiol Med; 2001 Sep; 102(3):109-21. PubMed ID: 11677451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of action of liver contrast agents: impact for clinical use.
    Clément O; Siauve N; Cuénod CA; Vuillemin-Bodaghi V; Leconte I; Frija G
    J Comput Assist Tomogr; 1999 Nov; 23 Suppl 1():S45-52. PubMed ID: 10608397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multifocal inflammatory pseudotumor of the liver: dynamic gadolinium-enhanced, ferumoxides-enhanced, and mangafodipir trisodium-enhanced MR imaging findings.
    Mortelé KJ; Wiesner W; de Hemptinne B; Elewaut A; Praet M; Ros PR
    Eur Radiol; 2002 Feb; 12(2):304-8. PubMed ID: 11870426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver-specific MR imaging contrast agents.
    Hahn PF; Saini S
    Radiol Clin North Am; 1998 Mar; 36(2):287-97. PubMed ID: 9520982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Magnetic resonance imaging of focal liver lesions. Comparison of the superparamagnetic iron oxide resovist versus gadolinium-DTPA in the same patient.
    Vogl TJ; Hammerstingl R; Schwarz W; Kümmel S; Müller PK; Balzer T; Lauten MJ; Balzer JO; Mack MG; Schimpfky C; Schrem H; Bechstein WO; Neuhaus P; Felix R
    Invest Radiol; 1996 Nov; 31(11):696-708. PubMed ID: 8915751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of approved MR contrast media for intravenous injection.
    Runge VM
    J Magn Reson Imaging; 2000 Aug; 12(2):205-13. PubMed ID: 10931582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocyte-targeted MR contrast agents: contrast enhanced detection of liver cancer in diffusely damaged liver.
    Tanimoto A; Kuribayashi S
    Magn Reson Med Sci; 2005; 4(2):53-60. PubMed ID: 16340158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications.
    Reimer P; Schneider G; Schima W
    Eur Radiol; 2004 Apr; 14(4):559-78. PubMed ID: 14986050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of hepatocellular carcinoma arising in cirrhotic livers: comparison of gadolinium- and ferumoxides-enhanced MR imaging.
    Tang Y; Yamashita Y; Arakawa A; Namimoto T; Mitsuzaki K; Abe Y; Katahira K; Takahashi M
    AJR Am J Roentgenol; 1999 Jun; 172(6):1547-54. PubMed ID: 10350287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of gadolinium chelates with manganese-DPDP for liver lesion detection and characterization: preliminary results.
    Kettritz U; Schlund JF; Wilbur K; Eisenberg LB; Semelka RC
    Magn Reson Imaging; 1996; 14(10):1185-90. PubMed ID: 9065909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined use of MR contrast agents for evaluating liver disease.
    Ward J; Robinson PJ
    Magn Reson Imaging Clin N Am; 2001 Nov; 9(4):767-802, vi. PubMed ID: 11694437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical focal nodular hyperplasia of the liver: imaging features of nonspecific and liver-specific MR contrast agents.
    Ba-Ssalamah A; Schima W; Schmook MT; Linnau KF; Schibany N; Helbich T; Reimer P; Laengle F; Wrba F; Kurtaran A; Ryan M; Mann FA
    AJR Am J Roentgenol; 2002 Dec; 179(6):1447-56. PubMed ID: 12438034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging liver metastases: review and update.
    Kanematsu M; Kondo H; Goshima S; Kato H; Tsuge U; Hirose Y; Kim MJ; Moriyama N
    Eur J Radiol; 2006 May; 58(2):217-28. PubMed ID: 16406434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of liver metastases: comparison of gadobenate dimeglumine-enhanced and ferumoxides-enhanced MR imaging examinations.
    del Frate C; Bazzocchi M; Mortele KJ; Zuiani C; Londero V; Como G; Zanardi R; Ros PR
    Radiology; 2002 Dec; 225(3):766-72. PubMed ID: 12461259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New MR contrast media in liver diagnosis. Initial clinical results with hepatobiliary Eovist (gadolinium-EOB-DTPA) and RES-specific Resovist (SH U 555 A)].
    Reimer P; Tombach B; Daldrup H; Hesse T; Sander G; Balzer T; Shamsi K; Berns T; Rummeny EJ; Peters PE
    Radiologe; 1996 Feb; 36(2):124-33. PubMed ID: 8867429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Superparamagnetic iron oxide--enhanced versus gadolinium-enhanced MR imaging for differential diagnosis of focal liver lesions.
    Vogl TJ; Hammerstingl R; Schwarz W; Mack MG; Müller PK; Pegios W; Keck H; Eibl-Eibesfeldt A; Hoelzl J; Woessmer B; Bergman C; Felix R
    Radiology; 1996 Mar; 198(3):881-7. PubMed ID: 8628887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced liver MR: contrast agents and imaging strategy.
    Runge VM; Kirsch JE; Wells JW; Awh MH; Bittner DF; Woolfolk CE
    Crit Rev Diagn Imaging; 1993; 34(1-2):1-30. PubMed ID: 8216813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Current status of the clinical development of MR contrast media].
    Laniado M; Kopp AF
    Rofo; 1997 Dec; 167(6):541-50. PubMed ID: 9465947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential use of gadolinium chelate and mangafodipir trisodium for the assessment of focal liver lesions: initial observations.
    Martin DR; Semelka RC; Chung JJ; Balci NC; Wilber K
    Magn Reson Imaging; 2000 Oct; 18(8):955-63. PubMed ID: 11121698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.